Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azacitidin AqVida
- Development stage
- Unknown
- Lead developer
- AqVida
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Azacitidin AqVida is a generic formulation of azacitidine, a pyrimidine nucleoside analog of cytidine that acts as a DNA methyltransferase (DNMT) inhibitor and epigenetic modulator. Developed and manufactured by the German pharmaceutical company AqVida, it is approved in Europe for the treatment of adult patients who are ineligible for hematopoietic stem cell transplantation (HSCT) and suffer from high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Azacitidin AqVida is administered as a subcutaneous injection. It works by incorporating into DNA and RNA, where it covalently binds to and inhibits DNA methyltransferases (primarily DNMT1, DNMT3A, and DNMT3B), leading to DNA hypomethylation and the reactivation of silenced tumor suppressor genes, as well as direct cytotoxicity in rapidly dividing abnormal hematopoietic cells.
- Brand names
- Azacitidin AqVidaAzacitidine AqVida
- Other names
- 5-azacitidine5-azacytidineazacitidinazacitidine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)
Beyond the preview
Go deeper on Azacitidin AqVida.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azacitidin AqVida.